These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 32353102)
1. Renal tuberculosis in an imatinib-treated chronic myeloid leukemia. Chandra A; Rao N; Malhotra KP J Bras Nefrol; 2020; 42(3):366-369. PubMed ID: 32353102 [TBL] [Abstract][Full Text] [Related]
2. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179 [TBL] [Abstract][Full Text] [Related]
3. Targeted chronic myeloid leukemia therapy: Seeking a cure. Fausel C Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932 [TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140 [TBL] [Abstract][Full Text] [Related]
5. t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia. Denčić-Fekete M; Đorđević V; Storlazzi CT; Janković G; Bogdanović A; Jovanović J; Rocchi M; Todorić-Živanović B; Strnad M; Gotić M Int J Hematol; 2009 May; 89(4):508-512. PubMed ID: 19322630 [TBL] [Abstract][Full Text] [Related]
6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Borthakur G; Cortes JE Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Nardi V; Azam M; Daley GQ Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206 [TBL] [Abstract][Full Text] [Related]
18. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204 [TBL] [Abstract][Full Text] [Related]
19. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib. Li C; Wang Y; Xu D; Zhang P; Ding X; Zhang N; Xiao M; Huang L; Meng L Clin Lab; 2015; 61(1-2):183-6. PubMed ID: 25807654 [TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Druker BJ Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]